Overview

HD17 for Intermediate Stage Hodgkin Lymphoma

Status:
Completed
Trial end date:
2020-03-23
Target enrollment:
Participant gender:
Summary
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
University of Cologne
Treatments:
Bleomycin
Cyclophosphamide
Dacarbazine
Doxorubicin
Etoposide
Liposomal doxorubicin
Prednisone
Procarbazine
Vinblastine
Vincristine